Business brief
Consolidation Under Fire
Regulators target media mergers while pharmaceutical giants double down on biotech acquisitions.
Business
States and writers are blocking what studios call their only survival play — if the lawsuits succeed, legacy entertainment giants will have to face streaming rivals at half the scale.
BackgroundParamount and Warner Bros. Discovery are among the world's largest entertainment conglomerates, controlling massive movie studios and cable networks. Merging them would create a dominant media giant, but it faces intense scrutiny from regulators wary of further industry consolidation.
- The 12-state coalition argues the merged entity would control nearly one-third of all movie theater releases and basic U.S. cable channels, sharply reducing choices for consumers.
- The Writers Guild of America alleges the consolidation would gut competition for writing talent, giving the combined firm immense leverage to depress creative wages and limit new projects.
- Paramount offered to delay closing the deal for 28 days to coordinate court schedules, signaling a desire to resolve the legal battle before the autumn television season begins.
Business
Eli Lilly is validating psychedelic medicine with its multi-billion-dollar buyout — cementing neuroplastogens as the next major clinical frontier for global pharmaceutical giants.
BackgroundPsychedelic compounds are showing significant clinical promise for treating chronic mental health conditions like depression and post-traumatic stress disorder. However, taking these complex substances through clinical trials is extremely expensive, requiring massive pharmaceutical backing to scale.
- Lilly will pay $2.8 billion upfront in cash, providing AtaiBeckley with immediate capital to fund its late-stage clinical pipelines, plus $1 billion in performance-based milestones.
- The acquisition centers on an intranasal formulation targeting treatment-resistant depression currently in Phase 3 trials, which could receive regulatory approval within the next two years.
- By adding neuropsychiatric candidates to its portfolio, Eli Lilly is positioning itself to lead a rapidly expanding market for alternative neurological therapeutics, diversifying beyond weight-loss drugs.
Business
Samsung Biologics is buying up European manufacturing capacity to dominate the peptide market — a strategic land grab that establishes South Korea as the production hub for weight-loss drugs.
BackgroundContract development and manufacturing organizations produce specialized drugs on behalf of other pharmaceutical companies. Demand for these facilities has soared globally, driven heavily by the unprecedented popularity of peptide-based weight-loss and diabetes treatments.
- The acquisition expands Samsung's manufacturing footprint across Switzerland, Sweden, Belgium, France, the US, and India, securing a highly diversified global supply chain.
- The transaction integrates specialized peptide active pharmaceutical ingredients into Samsung's portfolio, complementing its existing focus on large-scale antibody production.
- The cash deal positions Samsung to capture a massive share of the global GLP-1 manufacturing market, which currently faces severe manufacturing bottlenecks.
Business
Steam's record-breaking revenue shows the immense power of its platform lock-in — proving that dominant storefronts can easily withstand ongoing fee complaints from developers.
BackgroundSteam is the dominant digital distribution platform for PC video games, capturing the vast majority of global PC game downloads. The platform typically charges a standard 30% commission on sales, making it highly lucrative yet a frequent target for antitrust complaints.
- Legacy back-catalog titles accounted for 79% of Steam's gross revenue, proving that older games continue to generate reliable, long-term cash flow for major publishers.
- Growth was driven by a surge in active players across Asian markets and the return of prominent third-party publishers who previously tried running independent storefronts.
- Steam's estimated 75% market share remains a central focus of ongoing, developer-led antitrust lawsuits that accuse Valve of abusing its monopoly power.
Business
Business
Business
Unlock the full brief
Sign in to read every signal, takeaway, and source. Free account — Apple, Google, or email.